Phase 2 Depression and Anxiety Trial, By Invitation NCT07161700 Sponsor: Seaport Therapeutics Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, By Invitation

NCT07161700
By Invitation Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have already completed treatment in a related study called SPT-300-2024-203 (also known as the BUOY-1 Study), specifically those who attended the final scheduled visit (Visit 8, Day 42) of that study.
  • Women who could become pregnant must not be currently breastfeeding, must not be planning to become pregnant during the study, and must agree to use a highly effective form of contraception throughout the study and for 30 days after the last dose of the study treatment.
  • People who are willing and able to avoid using drugs of abuse for the duration of the study.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whom the study investigator, medical monitor, or study sponsor consider unsuitable for participation, for any reason.
  • People who, in the investigator's judgment, did not properly follow the procedures or take the study treatment as required during the earlier BUOY-1 Study.
  • Female participants who have a positive urine pregnancy test result, although those who have been surgically sterilised or who have been through menopause for at least 2 years may be enrolled without needing a negative test result (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Phase 2
Sponsor
Seaport Therapeutics
Registry
ClinicalTrials.gov
Start date
2 September 2025
Est. completion
1 May 2027

Where this trial is recruiting

🇧🇬 Bulgaria 🇨🇿 Czechia 🇩🇪 Germany 🇵🇱 Poland 🇸🇰 Slovakia 🇺🇸 United States

Primary endpoints

Safety and tolerability assessments based on Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and validated clinical scales and procedures

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov